Biopharma | 14 July 2026
Biocon’s Yesafili gains fresh clinical backing
As studies confirm comparable results to Eylea in eye disease treatment
As studies confirm comparable results to Eylea in eye disease treatment
The approval advances company’s goal of launching 20 biosimilar products in the U.S. by 2030
This marks a major step forward in the company’s efforts to develop advanced cell therapies for hard-to-treat cancers
Company consolidates 100% stake in subsidiary as it sharpens focus on biologics and biosimilars
Government-backed project aims to advance personalised chemotherapy screening using patient-derived tumour organoids
The proposed subsidiary will evaluate opportunities through joint ventures and strategic investments in innovative therapeutic areas
The buyer, Immunoscript Life Science Private Limited, is a newly incorporated company promoted by Dr. Sanjay Singh, who previously served as a Director of Gennova Biopharmaceuticals
Team NIB at XSeed Labs to develop human in vitro platform for accelerating discovery and validation of innovative intraocular biologics
The collaboration will test Apertura’s proprietary TfR1 CapX AAV capsid, a next-generation delivery technology designed to bind transferrin receptor 1 (TfR1)
The company has announced that its MFG8 drug substance manufacturing facility in Hebei successfully passed a US FDA Pre-License Inspection (PLI)
The acceptance of DMF #32973 strengthens Porton Advanced’s position in the fast-growing exosome therapeutics sector
The partnership highlights both companies’ commitment to increasing availability of high-quality biologic medicines while supporting more sustainable healthcare systems globally
The collaboration is expected to provide researchers and students with greater exposure to real-world drug development challenges
The incidents were reported to WHO by national regulatory authorities in the Maldives and Mexico in May and June 2026
The partnership will bring Arima’s genomic architecture tools to researchers studying epigenetics, gene regulation, human health and disease, as well as reference-quality genome assembly and haplotype phasing
The agreement, signed through Shilpa Medicare’s wholly owned subsidiary Shilpa Biologicals Private Limited, targets one of the world’s most widely used immuno-oncology medicines
India-Japan joint venture now manufactures over 100 molecular biology reagents and enzymes, strengthening Make in India, enabling Indian research and supporting Takara Bio’s global R&D programs from India
The sector is poised to transition from being the pharmacy of the world to becoming a global innovation powerhouse, say industry leaders
Partnership expands Avantor India's filtration portfolio, providing researchers and laboratories with enhanced access to Sartorius' high-performance filter papers backed by nationwide distribution and technical support
Itvisma is designed to target the underlying genetic cause of SMA by replacing the faulty SMN1 gene
Subscribe To Our Newsletter & Stay Updated
